Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
August 5, 2021 4:05 PM EDT
$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021)
415 patient start forms (PSFs) received for LUPKYNIS during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date
Continued ex-U.S. execution highlighted by the submission of a voclosporin MAA to the EMA by Otsuka
Cash and cash equivalents, and investments of $323.7 million at June 30, 2021
Conference call to be hosted today at 4:30 p.m. EDT
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial... More
